Patient Feedback Pioneers: Chronic Fatigue Advocates Prepare for First PDUFA V Meeting
This article was originally published in RPM Report
Executive Summary
FDA has selected CFS/ME as the first topic for the PDUFA V patient-centered drug development initiative. The lessons learned from this session will inform future work on patient engagement in drug development both for FDA—and for patient advocates.
You may also be interested in...
ALS Association Drafting Drug Development Guidance; Learning From DMD Advocacy
A Lou Gehrig’s disease patient advocacy group is moving forward with a drug development guidance of its own to the jumpstart the regulatory approval process.
PhRMA Wades Into FDA Patient-Focused Data Collection: Website Systems for Crowd-Sourced Info
Trade association partners with Genetic Alliance to provide input into FDA drug development initiative. That may be an effective intervention by PhRMA as it experiments with new ways to shape regulatory policy beyond traditional advocacy efforts.
Confluence of Symptoms and Treatments at FDA Patient Meetings
The first round of four PDUFA patient-focused meetings concluded with the Sept. 24 meeting on narcolepsy. FDA is beginning to look ahead to the fiscal 2014 meetings – to start with fibromyalgia on December 10. One pattern that is emerging is that three of the first five conditions discussed with patients have overlapping symptoms and treatments.